Tags

Type your tag names separated by a space and hit enter

RETRACTED ARTICLE

LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma.
Am J Clin Pathol. 2012 Jun; 137(6):971-7.AJ

Abstract

This study aimed to evaluate the relationship of LMX1A and osteopontin (OPN) expression with clinicopathologic parameters for the 4 most common ovarian surface epithelial carcinomas. Both biomarkers were investigated immunohistochemically using tissue microarrays of 249 specimens including 91 serous cystadenocarcinomas, 56 mucinous cystadenocarcinomas, 64 endometrioid adenocarcinomas, 26 clear cell carcinomas, and 12 normal ovarian tissues. All 4 carcinomas showed significant expression of LMX1A and OPN. In addition, higher immunostaining scores and percentage of cells stained for LMX1A in mucinous cystadenocarcinomas correlated with T stage, American Joint Committee on Cancer clinical stage, poorer tumor differentiation, and poorer survival rate. In serous cystadenocarcinoma, higher percentage of staining for OPN and higher intensity or immunostaining scores for LMX1A correlated with poorer tumor differentiation. Thus, the expression of LMX1A may be an independent prognostic risk factor in mucinous cystadenocarcinoma and a helpful marker in evaluating this tumor's aggressiveness.

Authors+Show Affiliations

Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, No. 325, Section 2, Cheng-Gong Road, Taipei, Taiwan.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Retracted Publication

Language

eng

PubMed ID

22586057

Citation

Lin, Chih-kung, et al. "LMX1A as a Prognostic Marker in Ovarian Mucinous Cystadenocarcinoma." American Journal of Clinical Pathology, vol. 137, no. 6, 2012, pp. 971-7.
Lin CK, Chao TK, Lai HC, et al. LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma. Am J Clin Pathol. 2012;137(6):971-7.
Lin, C. K., Chao, T. K., Lai, H. C., & Lee, H. S. (2012). LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma. American Journal of Clinical Pathology, 137(6), 971-7. https://doi.org/10.1309/AJCPIX0RUO5PGLXD
Lin CK, et al. LMX1A as a Prognostic Marker in Ovarian Mucinous Cystadenocarcinoma. Am J Clin Pathol. 2012;137(6):971-7. PubMed PMID: 22586057.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma. AU - Lin,Chih-kung, AU - Chao,Tai-Kuang, AU - Lai,Hung-Cheng, AU - Lee,Herng-Sheng, PY - 2012/5/16/entrez PY - 2012/5/16/pubmed PY - 2012/7/13/medline SP - 971 EP - 7 JF - American journal of clinical pathology JO - Am J Clin Pathol VL - 137 IS - 6 N2 - This study aimed to evaluate the relationship of LMX1A and osteopontin (OPN) expression with clinicopathologic parameters for the 4 most common ovarian surface epithelial carcinomas. Both biomarkers were investigated immunohistochemically using tissue microarrays of 249 specimens including 91 serous cystadenocarcinomas, 56 mucinous cystadenocarcinomas, 64 endometrioid adenocarcinomas, 26 clear cell carcinomas, and 12 normal ovarian tissues. All 4 carcinomas showed significant expression of LMX1A and OPN. In addition, higher immunostaining scores and percentage of cells stained for LMX1A in mucinous cystadenocarcinomas correlated with T stage, American Joint Committee on Cancer clinical stage, poorer tumor differentiation, and poorer survival rate. In serous cystadenocarcinoma, higher percentage of staining for OPN and higher intensity or immunostaining scores for LMX1A correlated with poorer tumor differentiation. Thus, the expression of LMX1A may be an independent prognostic risk factor in mucinous cystadenocarcinoma and a helpful marker in evaluating this tumor's aggressiveness. SN - 1943-7722 UR - https://www.unboundmedicine.com/medline/citation/22586057/LMX1A_as_a_prognostic_marker_in_ovarian_mucinous_cystadenocarcinoma_ L2 - https://academic.oup.com/ajcp/article-lookup/doi/10.1309/AJCPIX0RUO5PGLXD DB - PRIME DP - Unbound Medicine ER -